One of my personal highlights. History lesson with intersection of medicine. The hilarious @adamjbrown @RheumNow #ACR22 #rheuminations #factsperminute https://t.co/vDoKLsVfhB

Abst0327 #ACR22 SMART-SLE Monitoring Some SLE patients with +dsDNA have persistent positivity, others have fluctuations Anti-dsDNA in persistently positive HR 1.56 for flare risk Change (up or down!) in dsDNA more than 2x prior visit for fluctuating patients: HR 1.43 @RheumNow https://t.co/YwDPTYWPLu

Abst0324 #ACR22 How close are we to measuring Interferon Signature in clinical practice? NCounter and BioFire assays studied - correlated well we each other Genes: IFI27, IFI44L, IFIT1, RSAD2 SLE higher than RA or FMS, but does not correlate with SLE activity @RheumNow https://t.co/izpFtj9Pcd

Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SLE compared to controls AwMA predictive of death, AmtDNA and AmtRNA predictive of nephritis @Rheumnow https://t.co/d98HSHnJVE

Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis Factors for SLE transition: younger age, serositis, dsDNA SSc transition: puffy finger, NFC, or SSc antibodies No studies wo moderate or high risk of bias Limited studies on biomarkers for SLE, need more studies @Rheumnow https://t.co/GofGF8TkCx

All monster stories end with an unexpected award: A new order @cuttingforstone at #ACR22 tells the monster story of #covid “How will history review our story?” The science will get an A+, but we failed to learn the lessons of history All was predictable through history @RheumNow

Year in Review #ACR22 GLORIA Low steroid usage: lower DAS28, reduced joint damage BUT 24% increased adverse effects ⁦@RheumNow⁩ https://t.co/vYTAhoQEqr

Ab1012 #ACR22 @AlexisOgdie Opioid Use & Healthcare Utilization in PsA and AS 21% PsA pts on opioids, 27% AS on opioids Opioid users - more co-morbidities, 🚬, worse disease Tended to higher use of anti-rheumatic drugs Higher health care utilizations, medical $$ @RheumNow

@RheumNow Panel felt that weight and smoking recs were adequately covered by general health recommendations BUT, this misses a HUGE opportunity to stress that inflammatory arthritis pts have higher risks and need greater emphasis on modifiable risk factors than gen pop #ACR22 @RheumNow

CASIPSA results: CT SIJ characteristics from PsA pts similar to age- and sex-matched controls, but w/ higher prevalence of erosions, found in 18% of PsA patients. Abs 1012 #ACR22 https://t.co/jdUSUoUUbf https://t.co/2NQOhncYFc

• Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Art…

Look at these graphs and try and tell me that sex and gender doesn't matter in RA. We have seen in study after study after study - sex and gender matters. ABST0241 @erasmusmcintl #ACR22 @RheumNow https://t.co/GQnKrAp0eB https://t.co/MxHRy2kwDN

• https://twitter.com/TheLancetRheum/status/1572873396123504641

New IgG4-RD therapeutic avenues, mechanistically driven (B cell-CTL interaction): inebilizumab: registered for NMO, ph3 now obexelimab: novel dual MOA ?safer, ph3 now rilzabrutinib: BTKi, ph2 now elotuzumab: targets SLAMF7, MM registered, NIH study John Stone #ACR22 @RheumNow https://t.co/lx4bnCutlS